Skip to main contentWhat is the molecular structure of BPC-157?
BPC-157 is a synthetic pentadecapeptide — 15 amino acids, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, linear arrangement with no disulfide bridges. Published structural analyses confirm molecular formula C₆₂H₉₈N₁₆O₂₂, molecular weight 1419.53 g/mol, CAS number 137525-51-0 (PMID: 30915550). The compound derives from a partial sequence of human gastric juice protein — specifically a protective protein isolated from gastric mucosa. Four proline residues at positions 3, 4, 5, and 8 introduce conformational constraints that affect receptor approach geometry and metabolic stability against protease cleavage. N-terminal glycine and C-terminal valine bracket the active sequence. Published NMR spectroscopy data show that BPC-157 adopts a partially helical conformation in aqueous solution, with the central region exhibiting more ordered structure than the flexible termini (PMID: 22240337). Synthesis proceeds via solid-phase Fmoc chemistry, followed by preparative HPLC purification and lyophilization to a white to off-white powder that is soluble in water and standard aqueous buffers.
What is the origin of BPC-157?
The discovery trail for BPC-157 runs through gastric cytoprotection research. Published work first identified the compound during systematic investigation of protective factors in gastric mucosa — specifically a protein fraction exhibiting cytoprotective properties in tissue models (PMID: 15629827). The 15-amino acid fragment was subsequently isolated as the minimal active sequence retaining the protective effects seen in the full protein. The name Body Protection Compound reflects that original research context: identification of substances protecting gastric tissue from chemical and mechanical injury. Published literature traces the discovery to research conducted in the early 1990s, with early documentation covering isolation and characterization of cytoprotective effects in gastric tissue models (PMID: 16320866). The synthetic version replicates the naturally occurring sequence exactly — this is not a designed scaffold but a direct copy of an endogenous fragment. Published molecular biology studies confirm that the synthetic peptide exhibits equivalent physicochemical properties to the native fragment (PMID: 20309382), establishing that recombinant production does not alter the structural identity relevant to research applications.
What are the published mechanisms of action for BPC-157?
BPC-157 engages multiple interacting signaling pathways, with the nitric oxide system as a primary point of contact. Published studies demonstrate that BPC-157 affects NO synthesis and signaling in endothelial cell cultures and gastric tissue models — modulating eNOS activity and thereby influencing NO production that regulates vascular tone and blood flow (PMID: 35489163). That is the primary axis. Secondary pathways documented in published in vitro work include interaction with the GABAergic system: effects on GABA-A receptor function and chloride channel conductance in neuronal cell cultures (PMID: 26809810), plus modulation of dopaminergic pathways affecting dopamine synthesis and receptor activity in cell culture models. Growth factor signaling represents a third tier of documented interactions — BPC-157 affects VEGF and FGF receptor activity, influencing cell proliferation and migration in tissue culture studies (PMID: 30915550). Prostaglandin E2 synthesis and receptor signaling in epithelial cell cultures, along with NO-cGMP pathway activity and calcium signaling, round out the mechanistic picture from published preclinical data. These pathways are not independent — they form an interconnected network that makes BPC-157 a multi-target research compound.
What does published research show about BPC-157 and nitric oxide?
The NO pathway is the best-characterized mechanistic target for BPC-157. Research in endothelial cell cultures documents that BPC-157 affects eNOS expression directly, influencing NO production at the synthetic step (PMID: 35489163). NO is a critical regulator of vascular tone, blood flow, and intercellular signaling — its modulation has downstream consequences across multiple tissue systems. Published molecular studies demonstrate that BPC-157 influences NO-mediated responses in gastric tissue models, affecting protective mechanisms against chemical injury. The compound appears to enhance NO bioavailability through combined effects on synthesis and NO stabilization in tissue environments. Downstream from NO, published research documents interactions with the NO-cGMP pathway: BPC-157 affects cyclic GMP production, which in turn drives smooth muscle relaxation, platelet aggregation responses, and cellular stress adaptation. Tissue culture studies confirm correlation between BPC-157's NO signaling effects and observed changes in cellular function — the pathway is not theoretical but mechanistically connected to documented outputs. Published mechanistic work positions NO pathway modulation as the primary molecular mechanism through which BPC-157 exerts effects in preclinical models (PMID: 35489163).
How does BPC-157 affect growth factor pathways?
Published in vitro work characterizes BPC-157 as an active modulator of VEGF, FGF, and EGF signaling. Studies in fibroblast and endothelial cell cultures document effects on VEGF expression and VEGF receptor signaling, with downstream influence on angiogenic responses (PMID: 32786122). VEGF-A production appears elevated in cellular models treated with BPC-157, affecting vascular formation and remodeling parameters measurable in scratch assay and tube-formation protocols. FGF-2 signaling is also documented: BPC-157 influences fibroblast proliferation and extracellular matrix production in cell culture, with effects mediated through FGF receptor activation and downstream MAP kinase pathways. Research in epithelial cell cultures adds EGF receptor phosphorylation to the target list — BPC-157 affects EGF receptor signaling, influencing cell migration rates in wound closure assays. Published mechanistic studies confirm that growth factor pathway modulation is a genuine secondary mechanism contributing to the cellular proliferation, migration, and tissue remodeling effects documented in preclinical models (PMID: 30915550). These pathways are fundamental to tissue repair signaling networks, which positions BPC-157 as a multi-pathway probe for researchers investigating angiogenesis and matrix remodeling.
What is known about BPC-157 and neurotransmitter systems?
Three neurotransmitter systems have published preclinical characterization for BPC-157: GABA, dopamine, and serotonin. The GABA-A evidence base is the strongest — studies in neuronal cell cultures demonstrate effects on GABA-A receptor function including chloride channel conductance and GABAergic signal modulation, with documented effects on receptor subunit expression and trafficking (PMID: 26809810). Dopaminergic pathways are also characterized: BPC-157 influences dopamine synthesis, release, and receptor activity in neuronal cultures, including modulation of dopamine transporter function and receptor signaling downstream. Serotonin system interactions exist in the published literature but are less thoroughly characterized than the GABA and dopamine data sets. Published molecular research points to effects on synthetic enzymes and metabolic pathways as the mechanism, with documented influence on monoamine oxidase activity in biochemical assay formats affecting neurotransmitter degradation kinetics. Published studies are explicit on the data source: all neurotransmitter effects derive from cell culture and biochemical models. These findings provide mechanistic context and generate hypotheses for further investigation — they are not clinical findings and require validation across additional research approaches before broader conclusions can be drawn.
What is the amino acid sequence of BPC-157?
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Single-letter notation: GEPPPGKPADDAGLV. Published structural studies confirm this sequence via mass spectrometry and Edman degradation sequencing (PMID: 22240337). Several features of the sequence drive its behavior in research contexts. The Pro-Pro-Pro region at positions 3-5 introduces structural rigidity that constrains the local conformation — this proline cluster demands careful coupling conditions during solid-phase synthesis to avoid deletion sequences. Multiple acidic residues (Glu, Asp, Asp) affect solubility and charge across physiological pH ranges. The hydrophobic anchor residues (Leu, Val, Ala) at the C-terminal end balance the hydrophilic N-terminus. N-terminal glycine provides conformational flexibility; C-terminal valine provides the hydrophobic tail. The absence of cysteine eliminates disulfide bond formation entirely — this simplifies synthesis chemistry and makes the lyophilized powder straightforward to handle compared to disulfide-constrained peptides. Published circular dichroism studies indicate that the peptide in solution adopts random coil and partial helical structures, with the proline-rich region forming polyproline-type conformations that constrain the backbone geometry.
How does BPC-157 interact with cellular stress responses?
Three cellular stress response pathways have documented BPC-157 interactions in published preclinical work: oxidative stress, ER stress, and mitochondrial function. Studies in epithelial cell cultures document effects on antioxidant enzyme expression — BPC-157 influences superoxide dismutase and catalase levels, affecting the cellular redox balance and reactive oxygen species management (PMID: 24147114). The compound also modulates ROS production itself, not only the scavenging response. Heat shock protein expression is a documented secondary effect: BPC-157 affects HSP70 and HSP90 levels in cellular stress models, altering the availability of molecular chaperones that protect proteins under stress conditions. Published work on endoplasmic reticulum stress shows BPC-157 affecting unfolded protein response markers in cell culture — the ER stress axis connects to multiple downstream pathways relevant to cell survival and protein quality control. Mitochondrial data documents effects on membrane potential and ATP production, with BPC-157 influencing mitochondrial biogenesis markers and organelle dynamics. These stress response interactions provide the mechanistic basis for the cytoprotective properties documented in tissue culture systems — each pathway independently contributes to the cellular survival capacity that BPC-157 modulates.
What research applications does BPC-157 have?
BPC-157 serves as a research tool across several distinct experimental domains. Gastric tissue research uses the compound to interrogate protective mechanisms against chemical injury and oxidative damage in mucosal cell cultures (PMID: 11929096). Wound healing protocols apply BPC-157 to investigate fibroblast migration rates, collagen synthesis kinetics, and angiogenic responses in tissue culture and explant models. Vascular research uses BPC-157 to examine endothelial cell function, angiogenesis endpoints, and vascular remodeling in vitro. Neuroscience applications leverage the documented neurotransmitter pathway interactions for mechanistic studies of GABA, dopamine, and serotonin signaling in cell culture. Connective tissue research — tendons, ligaments, extracellular matrix — rounds out the primary application areas. Published studies are consistent on the experimental scope: cell cultures, tissue explants, and biochemical assays — not controlled clinical investigations. Research protocols require ≥99% HPLC-verified purity compounds with documented mass spectrometry identity confirmation and batch-specific Certificates of Analysis. Published in vitro work typically uses 1-100 μg/mL concentration ranges in cell culture media, with duration and endpoint selection driven by the specific assay format.
What is the current state of BPC-157 research?
The BPC-157 literature is primarily preclinical: cell cultures, tissue models, biochemical assays. Published review articles characterize the body of work as preliminary — mechanistic studies have generated insights into molecular pathways, but the evidence base lacks the rigorous validation required for clinical translation (PMID: 24147114). The documented mechanistic picture includes NO pathway modulation, growth factor signaling, and neurotransmitter interactions across multiple model systems. Tissue culture evidence spans gastric, vascular, and neuronal systems. What the literature lacks is large-scale, well-controlled investigation — the current evidence base is hypothesis-generating, not hypothesis-confirming. Published work identifies additional mechanistic clarification as a priority: receptor identity, signaling hierarchy, and dose-response relationships need independent replication before conclusions become stable. Quality and methodological concerns exist in portions of the published literature, and systematic reviews call for standardized protocols and independent replication of key findings. Research-grade BPC-157 with documented purity and identity enables investigators to design mechanistically rigorous studies that address the reproducibility gaps the existing literature has identified.
FAQ
What is the molecular weight of BPC-157?
The molecular weight of BPC-157 is 1419.53 g/mol (monoisotopic) or 1419.64 g/mol (average). Published mass spectrometry studies confirm this molecular weight with high accuracy (PMID: 22240337).
What is the CAS number for BPC-157?
The CAS Registry Number for BPC-157 is 137525-51-0. This unique identifier distinguishes it from related compounds and provides standardized reference for chemical databases and regulatory documentation.
How stable is BPC-157 during storage?
Lyophilized BPC-157 is stable at -20°C for 24+ months. The peptide is susceptible to oxidation and hydrolysis in solution. Published stability studies recommend aliquoting into single-use volumes and storing at -20°C or -80°C (PMID: 30915550).
What concentration is used in cell culture research?
Published in vitro studies typically use BPC-157 concentrations of 0.1-100 μg/mL, with 1-10 μg/mL being most common. Concentrations vary by cell type and experimental design. Always verify viability at planned concentrations.
Does BPC-157 form disulfide bonds?
No, BPC-157 contains no cysteine residues and cannot form disulfide bonds. This simplifies synthesis and handling compared to disulfide-containing peptides. The linear structure remains the active form.
Research Use Only: All compounds sold by Onward Aminos are intended exclusively for laboratory research. Not for human or animal consumption. These products are not drugs, supplements, or food. Statements have not been evaluated by the FDA. Must be 21+ to purchase.